Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
- 1 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21), 5638-5645
- https://doi.org/10.1158/1078-0432.ccr-20-1899
Abstract
Purpose: Pleomorphic dermal sarcoma (PDS) is a rare malignant cutaneous tumor with an unknown cell of origin. Locally defined tumors can be treated by curative excisions, whereas advanced stages of the disease are difficult to treat, using standard regimens. Experimental Design: We performed whole exome sequencing on a cohort of 28 individuals and corresponding transcriptomic analysis on 21 patients, as well as quantitative immunohistochemical image analysis on 27 patients. Results: PDS exhibits a universally high mutational load (42.7 mutations per mega base) with an inflamed, immunogenic tumor microenvironment. Three cases of PDS showed response to immune checkpoint blockade. Local mutation rate variation together with mRNA expression data demonstrate that PDS form a distinct entity, with PDGFRB as a lineage marker. In addition, we found that PDS is of mesenchymal, fibroblastic differentiation. Conclusion: PDS is of fibroblastic differentiation and exhibits a strong susceptibility to immunotherapy, including a high mutational burden and an inflamed tumor microenvironment.Keywords
Other Versions
Funding Information
- Deutsche Forschungsgemeinschaft (SFB829)
- Deutsche Forschungsgemeinschaft (SFB1399)
- BMBF (01ZX1901)
- Else Kröner-Fresenius-Stiftung (2016_Kolleg.19)
This publication has 35 references indexed in Scilit:
- Mutational Landscape of Aggressive Cutaneous Squamous Cell CarcinomaClinical Cancer Research, 2014
- Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumorsExpert Opinion on Pharmacotherapy, 2014
- TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasLaboratory Investigation, 2014
- Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-upClinical Cancer Research, 2014
- Signatures of mutational processes in human cancerNature, 2013
- Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2013
- Pleomorphic Dermal SarcomaThe American Journal of Surgical Pathology, 2012
- CDKN2A but not TP53 mutations nor HPV presence predict poor outcome in metastatic squamous cell carcinoma of the skinInternational Journal of Cancer, 2009
- Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II studyBritish Journal of Haematology, 2008
- Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective studyThe Lancet Oncology, 2008